Spruce Biosciences (SPRB)

• Market cap: $5.9M
• 1 day: 5.27%
• 5 days: 11.92%
• 1 month: -57.59%
• 3 months: -63.37%
• 6 months: -76.09%
• Year to date: -66.64%
• 1 year: -80.07%
• 5 years: -99.18%
• 10 years: -99.18%
• Sector: Healthcare
• Industry: Biotechnology

About: Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).

Employees: 21

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

3% more funds holding

Funds holding: 29 [Q3] → 30 (+1) [Q4]

5.89% less ownership

Funds ownership: 32.93% [Q3] → 27.03% (-5.89%) [Q4]

27% less capital invested

Capital invested by funds: $6.4M [Q3] → $4.69M (-$1.71M) [Q4]

50% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 10

100% less funds holding in top 10

Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $0.50 257% upside
• Avg. target: $0.50 257% upside
• High target: $0.50 257% upside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

RBC Capital Gregory Renza 19% 1-year accuracy 14 / 73 met price target

257% upside $0.50

Sector Perform Maintained

16 Apr 2025